2025 Partners
Program Partner
Adimab
Adimab is the most successful antibody discovery company in the industry, with 450+ discovery campaigns and 55+ clinical programs created with more than 100 partners. Our unique, yeast-based platform is a comprehensive and effective tool for the discovery and optimization of fully human monoclonal and bispecific antibodies. Our partners range from some of the biggest pharma to biotech companies at all stages to leading academic institutions. We’re committed to staying at the cutting edge
of protein-based therapeutic discovery to enable the highest quality IgGs, multispecifics, CARs and other modalities to allow our partners to have the most successful therapeutic programs possible.
Program Partner
Alloy Therapeutics
Alloy Therapeutics accelerates the drug discovery process by providing access to best-in-class foundational drug discovery platforms, services, and company creation capabilities. Alloy Therapeutics has developed novel strains for fully human antibody discovery and created innovative technology to support a multitude of modalities that can help to quickly identify candidates. Leveraging our world class scientists, Alloy therapeutics platforms and services enables you to build a more robust antibody-based therapeutic pipeline.
Hosting Partner
Miltenyi Biotec
Miltenyi Biotec is a global leader in innovating technologies and services for patient-specific cell and gene therapies, transforming scientific discoveries into practical treatments for personalized medicine. With over 35 years of expertise, it supports biomedical discoveries and translates them into clinical applications, enhancing patient access to new therapies. Miltenyi Biotec focuses on offering integrated solutions for complex challenges in treating cancers, autoimmune diseases, and inherited disorders. Its Miltenyi Bioindustry division provides expert guidance to therapy developers efficiently from process development to commercialization. Headquartered in Bergisch Gladbach, it employs 4,900 people across 24 countries.
Innovation Partner
BioMedX
BioMed X is an independent research institute with locations in Heidelberg, Germany, New Haven, and an open innovation incubator at Boehringer Ingelheim's R&D campus in Ridgefield, Connecticut, along with a global partner network. At the intersection of academia and industry, we drive pioneering research in oncology, immunology, neuroscience, platform technologies, and artificial intelligence. Supported by leading pharmaceutical companies, our projects are led by early-career scientists recruited from top institutions worldwide. Through global crowdsourcing and local incubation, we tackle major biomedical R&D challenges. With a focus on curiosity-driven exploration and rigorous validation, we advance translational biomedicine and foster cross-disciplinary innovation. Our research has also resulted in the development of new technologies for the pharmaceutical and biotech industries, such as T-Finder.
Exhibition Partner
Promega
Promega provides a broad portfolio of functional bioassays, immunoassays, and protein characterization tools to accelerate your cell therapy drug discovery and development. We offer state-of-the-art reporter and health assays for potency testing, tools for TCR discovery, and antigen specificity. All of our products are developed and manufactured under rigorous quality standards and our bioassays are pre-qualified according to ICH guidelines. Connect with us so we can help support your assay needs today!
Exhibition Partner
Alithea Biotechnology GmbH
Alithea Biotechnology GmbH (GER) is providing cutting-edge HLA peptidomics technologies for target discovery, validation and off-target toxicity profiling since 2019. Alithea has a web-accessible quantitative HLA peptide database, HLA-Compass, allowing to navigate peptide presentation in health and cancer. Proprietary HLA peptide binding predictors and strong experience in the quantification of HLA ligands together with most sensitive timsToF Ultra-powered mass spectrometry equipment facilitate high quality and sensitivity. Proteogenomics capabilities and an in-house repository of HLA typed tissue samples facilitate rapid validation of hypotheses for TCR/TCRm drug discovery. Alithea happily supports you in solving RnD challenges from target discovery to IND submission.
Exhibition Partner
Made Scientific
Made Scientific is a leading cell therapy contract development and manufacturing organization (CDMO) dedicated to advancing the field of cell therapy. Since 2019, the company has specialized in developing, manufacturing, and releasing autologous and allogeneic cell therapy products for early- to mid-stage clinical trials, and has evolved into an end-to-end clinical-to-commercial service provider. Operating from two U.S.-based manufacturing facilities, Made Scientific combines the flexibility and entrepreneurial spirit of a specialist CDMO with the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors.
Exhibition Partner
BPS Bioscience
BPS Bioscience strives to advance new scientific discoveries that lead to therapies by creating innovative research solutions. We drive advancements across a broad range of critical research areas, providing 4500+ recombinant cell lines, virus-based tools, proteins, biochemical and cell-based assay kits, and compound screening focused on drug discovery.